Cadrenal Therapeutics reported second quarter 2026 financial results and provided a corporate update. The company incurred research and development expenses of $0.7 million and general and administrative expenses of $2.6 million, resulting in a net loss of $3.3 million for the quarter ended June 30, 2026. As of early August 2026, Cadrenal held approximately $4.2 million in cash and cash equivalents, which is expected to fund operations through the first quarter of 2027. The company launched a structured strategic partnering process for its Cardiac Acute Critical Care Franchise assets, including CAD-1005, frunexian, and tecarfarin. Additionally, Cadrenal signed an agreement with a global firm to secure non-dilutive funding and completed a private placement generating approximately $3.0 million in gross proceeds, with up to $5.8 million additional potential proceeds if warrants are exercised. The company operates as a late-stage biopharmaceutical firm advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions.
